Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer. (Record no. 1775)

MARC details
000 -LEADER
fixed length control field 04716nam a22008657a 4500
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 160603s20162016 xxu||||| |||| 00| 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 0804-4643
040 ## - CATALOGING SOURCE
Original cataloging agency Ovid MEDLINE(R)
099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC)
PMID 26671977
245 ## - TITLE STATEMENT
Title Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
251 ## - Source
Source European Journal of Endocrinology. 174(3):373-80, 2016 Mar.
252 ## - Abbreviated Source
Abbreviated source EUR. J. ENDOCRINOL.. 174(3):373-80, 2016 Mar.
253 ## - Journal Name
Journal name European journal of endocrinology / European Federation of Endocrine Societies
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Year 2016
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Manufacturer FY2016
266 ## - Date added to catalog
Date added to catalog 2016-06-03
520 ## - SUMMARY, ETC.
Abstract CONCLUSIONS: These data demonstrate that sunitinib exhibits significant anti-tumor activity in patients with advanced DTC. Since sunitinib was relatively well-tolerated, there is the potential for clinical benefit in these patients, and further investigation of this agent is warranted.Copyright © 2016 European Society of Endocrinology.
520 ## - SUMMARY, ETC.
Abstract DESIGN AND METHODS: This was a single center, nonrandomized, open-label, phase 2 clinical trial. In total, 23 patients were enrolled and were treated with a starting daily, oral dose of 37.5 mg sunitinib. Patients were evaluated with imaging, laboratory tests, and physical examination periodically per protocol.
520 ## - SUMMARY, ETC.
Abstract OBJECTIVE: Our objective was to evaluate the efficacy and safety of sunitinib following at least one course of radioactive iodine treatment in patients with advanced differentiated thyroid cancer (DTC). The study endpoints included best response rate (including best objective response rate) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, measurement of serum thyroglobulin (Tg), and toxicity evaluation.
520 ## - SUMMARY, ETC.
Abstract RESULTS: The mean best response was a decrease of 17.2% (S.D. 22.8) in tumor sum from baseline. Six (26%) patients achieved a partial response (PR), and 13 (57%) had stable disease (SD) for a clinical benefit rate (PR+SD) of 83%. The overall median PFS was 241 days (interquartile limits, 114-518). No statistically significant difference was observed between the medians of the baseline and post-treatment Tg values (P=0.24). The most common adverse events included grades 1 and 2 decreases in blood cell counts (especially leukocytes), diarrhea, fatigue, hand-foot skin reaction, nausea, musculoskeletal pain, and hypertension.
546 ## - LANGUAGE NOTE
Language note English
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Adenocarcinoma, Follicular/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Antineoplastic Agents/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Bone Neoplasms/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Carcinoma/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Indoles/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Iodine Radioisotopes/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Lung Neoplasms/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Pyrroles/tu [Therapeutic Use]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Radiotherapy
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element *Thyroid Neoplasms/dt [Drug Therapy]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adenocarcinoma, Follicular/pa [Pathology]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged, 80 and over
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Bone Neoplasms/sc [Secondary]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Carcinoma/pa [Pathology]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Chemotherapy, Adjuvant
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Diarrhea/ci [Chemically Induced]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Disease-Free Survival
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Fatigue/ci [Chemically Induced]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Hand-Foot Syndrome/et [Etiology]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Leukopenia/ci [Chemically Induced]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Lung Neoplasms/sc [Secondary]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Male
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Nausea/ci [Chemically Induced]
650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Thyroid Neoplasms/pa [Pathology]
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Health Research Institute
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Heart & Vascular Institute
651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME
Institution MedStar Washington Hospital Center
656 ## - INDEX TERM--OCCUPATION
Department Medicine/Endocrinology
656 ## - INDEX TERM--OCCUPATION
Department Radiology
657 ## - INDEX TERM--FUNCTION
Medline publication type Clinical Trial, Phase II
657 ## - INDEX TERM--FUNCTION
Medline publication type Journal Article
657 ## - INDEX TERM--FUNCTION
Medline publication type Research Support, Non-U.S. Gov't
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Barett, Christina
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Bikas, Athanasios
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Burman, Kenneth D
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Clark, Brandon G
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Desale, Sameer
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Gandhi, Rahul
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Jelinek, James S
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Kundra, Priya
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Mete, Mihriye
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors O'Keefe, Kaitlyn
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Wartofsky, Leonard
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Wexler, Jason
700 ## - ADDED ENTRY--PERSONAL NAME
Local Authors Wray, Lynette
790 ## - Authors
All authors Barett C, Bikas A, Burman KD, Clark BG, Desale S, Gandhi R, Jelinek JS, Kundra P, Mete M, O'Keefe K, Wartofsky L, Wexler JA, Wray L
856 ## - ELECTRONIC LOCATION AND ACCESS
DOI <a href="http://dx.doi.org/10.1530/EJE-15-0930">http://dx.doi.org/10.1530/EJE-15-0930</a>
Public note http://dx.doi.org/10.1530/EJE-15-0930
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Koha item type Journal Article
Item type description Article
Holdings
Withdrawn status Lost status Damaged status Not for loan Collection Home library Current library Date acquired Total Checkouts Full call number Barcode Date last seen Date last checked out Price effective from Koha item type
          MedStar Authors Catalog MedStar Authors Catalog 06/03/2016 1 26671977 26671977 09/26/2017 09/26/2017 06/03/2016 Journal Article

Powered by Koha